Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients

Next Previous
Trial Profile

Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GALE 301 (Primary) ; GALE 302 (Primary) ; Sargramostim
  • Indications Breast cancer; Male breast cancer; Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors Galena Biopharma

Most Recent Events

  • 09 Mar 2017 Status changed from active, no longer recruiting to completed, as reported in a Galena Biopharma media release.
  • 12 Dec 2016 According to a Galena Biopharma media release, data from this study were presented as a poster at the San Antonio Breast Cancer Symposium (SABCS).
  • 12 Dec 2016 Results published in the Galena Biopharma Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top